Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sandra L Close"'
Autor:
S. Fossceco, L. O'Brien, Joe G.N. Garcia, Ivor S. Douglas, Jonathan Janes, Mark D. Williams, Jean Louis Vincent, Gordon R. Bernard, M. Man, Amy G Leishman, Andrew D. Shaw, Didier Payen, Robert J. Kaner, Sandra L Close
Publikováno v:
The Pharmacogenomics Journal. 13:218-226
Management of severe sepsis, an acute illness with high morbidity and mortality, suffers from the lack of effective biomarkers and largely empirical predictions of disease progression and therapeutic responses. We conducted a genome-wide association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3243fe311658b28844e1a1786aa489b1
https://doi.org/10.1038/tpj.2012.1
https://doi.org/10.1038/tpj.2012.1
Autor:
Sandra L Close
Publikováno v:
Fundamental & Clinical Pharmacology. 26:19-26
Pharmacogenetics have been touted as the future of personalized medicine where genetic biomarkers will guide therapeutic approach. The currently approved thienopyridines, prasugrel and clopidogrel, are prodrugs requiring conversion to active metaboli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed021391f28a64dec3b1f4b507dcee0d
https://doi.org/10.1111/j.1472-8206.2011.00983.x
https://doi.org/10.1111/j.1472-8206.2011.00983.x
Publikováno v:
Cardiovascular Therapeutics. 30:e174-e182
Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa3599b62ac34e08dd52cc397a882ad1
https://doi.org/10.1111/j.1755-5922.2011.00263.x
https://doi.org/10.1111/j.1755-5922.2011.00263.x
Autor:
Sandra L Close, Stuart Hobbs, Lawrence J. Lesko, Michael Pacanowski, Linda Surh, Arlene R Hughes, Susanne B. Haga, Nadine Cohen, Michael Mosteller, Scott Gottlieb, Marisa Papaluca-Amati, Myong-Jin Kim, Scott D. Patterson, Issam Zineh, Bryan Dechairo
Publikováno v:
Pharmacogenomics. 11:1637-1647
The 2010 US FDA–Drug Industry Association (DIA) Pharmacogenomics (PGx) Workshop follows a series that began in 2002 bringing together multidisciplinary experts spanning regulatory authorities, medical research, healthcare and industry. This report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc11c12f1a71f3198efeafc101270f09
https://doi.org/10.2217/pgs.10.138
https://doi.org/10.2217/pgs.10.138
Autor:
Ansar Jawaid, Timothy W. Robison, Sandra L Close, Ian Hunt, Sharada Louis Truter, Huixiao Hong, Catherine Cornu-Artis, Michael E. Burczynski, Laurent Essioux, Li Zhang, Peter Morrow, Weida Tong, Federico Goodsaid, Rosane Charlab, Issam Zineh, Shashi Amur, Lois Hinman, Lawrence J. Lesko, James T. Mayne, David Laurie, Kevin Carl, David Jacobson-Kram, Jacky Vonderscher, Jiri Aubrecht, Jennifer Catalano, Ina Schuppe-Koistinen, Marisa Papaluca-Amati, Leming Shi, Albert J. Fornace, Heng-Hong Li, Klaus Lindpaintner, Olivia Spleiss, Agnes Westelinck, John Roth
Publikováno v:
Nature Reviews Drug Discovery. 9:435-445
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e2e34f16439e789f9572e1eb16801aa
https://doi.org/10.1038/nrd3116
https://doi.org/10.1038/nrd3116
Autor:
Elliott M. Antman, Lei Shen, Stephen D. Wiviott, William L. Macias, Eugene Braunwald, John T. Brandt, Marc S. Sabatine, Sandra L Close, Joseph R. Walker, Richard D. Hockett, Jessica L. Mega
Publikováno v:
Circulation. 119:2553-2560
Background— Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of reduced-function CYP2C19 alleles have significantly lower levels of act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c877cd3d9afe3fc96b8da76fee194360
https://doi.org/10.1161/circulationaha.109.851949
https://doi.org/10.1161/circulationaha.109.851949
Autor:
Agneta Siegbahn, Stefan James, John T. Brandt, Christoph Varenhorst, Michael Man, David Erlinge, Oscar Ö. Braun, Joseph R. Walker, Lars Wallentin, Kenneth J. Winters, Sandra L Close
Publikováno v:
European Heart Journal
Aims The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df9ad9415bea17ee442980c4737ae8c
http://europepmc.org/articles/PMC2709885
http://europepmc.org/articles/PMC2709885
Autor:
Stephen D. Wiviott, Richard D. Hockett, Marc S. Sabatine, William L. Macias, Joseph R. Walker, Elliott M. Antman, John T. Brandt, Jessica L. Mega, Lei Shen, Eugene Braunwald, Sandra L Close
Publikováno v:
New England Journal of Medicine. 360:354-362
Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.We tested the association bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7778b514341d4d63e357b29c169942fe
https://doi.org/10.1056/nejmoa0809171
https://doi.org/10.1056/nejmoa0809171
Autor:
John P. Houston, Alan Breier, Sandra L Close, Ann Catherine M. Downing, Mark W. Farmen, David H. Adams
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 23:267-274
Objective To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods Eighty-eight acutely ill patients with schizophrenia or schizoaffective dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f19a3b02a406bdf074519340c2785b5
https://doi.org/10.1002/hup.930
https://doi.org/10.1002/hup.930
Autor:
Vassilis Georgoulias, Ki Hyeong Lee, Neil W. Gibson, Vikram K. Chand, Salih Zeki Guclu, Nicholas F. Dupuis, Enriqueta Felip, Dolores Isla, Erdem Göker, Flavio Solca, Sandra L. Close, Glenwood D. Goss, Jean-Charles Soria, Young Joo Min, E. Ehrnrooth, Konstantinos N. Syrigos, Nicole C. Krämer, Manuel Cobo, Alessandro Morabito
Publikováno v:
Journal of Clinical Oncology. 34:e20510-e20510
e20510Background: Treatment (tx) options for patients (pts) with advanced SCC of the lung after progression on platinum-based chemotherapy are limited. In LL8, the irreversible ErbB family blocker, A, significantly improved OS, PFS and disease contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88554f1ab8eff04482a1d0162df42993
https://doi.org/10.1200/jco.2016.34.15_suppl.e20510
https://doi.org/10.1200/jco.2016.34.15_suppl.e20510